It has been a remarkable year for anyone paying attention to weight loss treatment in the UK. Twelve months ago, GLP-1 medicines meant one thing: a weekly injection. In 2026, that assumption has been turned on its head twice over, first with the arrival of the Wegovy pill in June, and then with the MHRA’s authorisation of Foundayo on 10 August, making the UK the first country in Europe to approve this needle-free tablet. For patients who have spent years weighing up whether an injection pen fits into their life, this year has quietly rewritten the rules.
At Everest Pharmacy, we have watched this shift play out in real time, through the questions our patients ask, the treatments they choose, and the concerns that no longer come up as often as they used to. This article looks at how the landscape has actually changed in 2026, what oral GLP-1 medicines mean for patients who previously ruled out weight loss treatment altogether, and where things may be heading next. If you would like to understand where you fit into this changing picture, contact our team for a conversation about your options.
Where The Weight Loss Landscape Stood Before 2026
To understand why this year matters, it helps to remember where things stood before it. Since their emergence, GLP-1 medicines such as Wegovy and Mounjaro transformed private weight loss treatment in the UK, offering results that far exceeded what most previous medications had achieved. But there was a consistent, well-documented barrier: every effective GLP-1 option required a weekly self-injection.
For a significant number of patients, this was more than a minor inconvenience. Needle anxiety, discomfort with self-injecting, and simply a strong preference to avoid injections altogether kept many people from starting treatment they might otherwise have benefited from. Pharmacies, including Everest Pharmacy, regularly heard the same feedback: patients wanted the results GLP-1 medicines could offer, without the injection that came attached to them.
June 2026: The Wegovy Pill Changes The Conversation
The approval and implementation of the Wegovy pill in June 2026 was the first real answer to that demand. As an oral form of semaglutide, the same active ingredient used in the Wegovy injection, the pill gave patients access to a clinically established GLP-1 medicine without needing to inject it.
The trade-off was in how the tablet needed to be taken. Because semaglutide is a peptide that would otherwise be broken down during digestion, the Wegovy pill relies on a specific absorption enhancer that only works reliably when taken on an empty stomach, with a small amount of water, followed by a wait of at least thirty minutes before eating or drinking anything else. For many patients, this was a manageable routine to build into their morning. For others, particularly those with unpredictable schedules or shift patterns, it introduced a new kind of daily discipline that some found difficult to sustain.
Even with that limitation, the impact was significant. Patients who had previously avoided GLP-1 treatment purely because of the injection now had a genuine alternative, and demand for the Wegovy pill through Everest Pharmacy and our online partner platform, Everslim, reflected exactly that. You can read more detail on how this medicine compares in our guide to the Wegovy pill.
August 2026: Foundayo Authorisation Raises The Bar Again
Barely two months later, the landscape shifted again. On 10 August 2026, the MHRA authorised orforglipron, branded as Foundayo, making the UK the first country in Europe to approve this GLP-1 tablet for both weight management and type 2 diabetes.
What makes Foundayo notable is not simply that it is another oral GLP-1 medicine, but that it addresses the very limitation the Wegovy pill introduced. Foundayo is built as a small molecule rather than a peptide, meaning it does not rely on the same absorption enhancer and does not require the strict empty-stomach rule. Early information suggests it can be taken at any time of day, with or without food, and without specific water restrictions. In practical terms, this removes one of the last remaining pieces of daily friction associated with oral GLP-1 treatment.
Foundayo has not yet launched for prescribing, and providers, including Everest Pharmacy, are currently working through supply and clinical pathway arrangements ahead of its introduction. But its authorisation alone marks a second major milestone in a single calendar year, something the weight loss treatment sector has not seen before at this pace. For a closer look at Foundayo specifically, our dedicated guide on oral and GLP-1 treatment options covers what is known so far.
How The Options Compare Heading Into Late 2026
With three distinct GLP-1 approaches now either available or imminent, patients are in a genuinely different position to where they stood at the start of the year.
| Treatment | Form | Timing Requirements | UK Status (as of August 2026) |
|---|---|---|---|
| Mounjaro (tirzepatide) | Weekly injection | None | Established, widely available |
| Wegovy injection (semaglutide) | Weekly injection | None | Established, widely available |
| Wegovy pill (oral semaglutide) | Daily tablet | Empty stomach, 30 minutes before food | Approved and implemented June 2026 |
| Foundayo (orforglipron) | Daily tablet | None reported | Authorised 10 August 2026, launching soon |
This range of options means the decision is no longer simply “injection or nothing.” Patients can now weigh up format, daily routine, and personal preference alongside effectiveness, something that was not possible this time last year.
Why This Matters Beyond Convenience
It would be easy to frame 2026’s developments purely as a story about convenience, but the implications run deeper than that. A meaningful number of patients who could clinically benefit from GLP-1 treatment have never started it, specifically because of the injection. This is not a small or unusual group. Needle aversion is a genuine, well-recognised barrier to treatment, not a minor preference.
By removing that barrier, first partially with the Wegovy pill and then more fully with Foundayo, 2026 has effectively widened access to a category of medicine that many patients had already written off as not for them. This is arguably the more significant story than any single headline weight loss percentage, because it changes who is able to consider treatment in the first place, not just how effective that treatment might be for those already willing to inject.
What Hasn’t Changed
For all the change this year has brought, some things remain exactly as they were. GLP-1 medicines, whatever their form, still require a proper clinical assessment before they can be prescribed. Eligibility still depends on factors such as BMI, medical history and current medications. Side effects, largely gastrointestinal in nature, remain a consideration across every option, oral or injectable. And none of these treatments are designed to work in isolation, they are intended to support a broader plan involving diet and physical activity, not to replace it.
It is also worth noting that injectable options still lead on raw effectiveness figures. Mounjaro in particular continues to produce some of the highest average weight loss results of any GLP-1 treatment currently available in the UK, and this is unlikely to change simply because oral alternatives have become more convenient. For many patients, especially those focused primarily on maximum results, an injection may remain the more suitable choice even now.
What This Means For Patients Deciding Now
For anyone weighing up their options in the second half of 2026, the practical question has shifted from “am I willing to inject” to something more nuanced: what balance of convenience, routine and effectiveness matters most to you.
Patients who prioritise the strongest possible results may still be best served by an injectable option such as Mounjaro. Patients who want an oral medicine but are comfortable with a consistent morning routine may find the Wegovy pill suits them well. And patients who want maximum flexibility, without timing restrictions built around meals, are likely to be watching Foundayo’s launch closely.
None of these are objectively “better” choices in isolation. What matters is which option fits realistically into your life, because the treatment you can actually stick to consistently will always outperform, in practice, the one that looks best on paper but proves difficult to maintain.
Looking Ahead: What Might 2027 Bring
If 2026 has taught the weight loss treatment sector anything, it is that the pace of change is no longer slow and predictable. With Foundayo’s UK authorisation arriving less than a year after semaglutide’s oral form reached patients, further developments, whether from existing manufacturers refining their formulations or new entrants to the market, seem increasingly likely.
For now, the most useful thing patients can do is stay informed rather than wait indefinitely for the next development. Treatment that is started and maintained consistently tends to produce better outcomes than treatment repeatedly delayed in anticipation of something better arriving next.
How Everest Pharmacy Can Help You Navigate These Changes
With so much having changed this year, it is entirely understandable if patients feel unsure where to start. At Everest Pharmacy, and through our online partner platform, Everslim, our role is to help you make sense of the current landscape based on your own circumstances, rather than simply pointing you towards the newest option available.
Whether you are considering an injectable treatment, the Wegovy pill, or want to be notified as soon as Foundayo becomes available, our team can talk you through what each option genuinely involves and help you decide what fits your life. You can explore our full range of options on our weight loss services page, or start a conversation with our team directly.
Frequently Asked Questions
Has the Wegovy pill replaced the Wegovy injection for most patients?
No. Both remain available, and many patients still choose the injection, particularly if maximum effectiveness or avoiding a daily tablet routine is the priority. The pill has simply widened choice rather than replacing the injection.
Why did it take until 2026 for an oral GLP-1 medicine to become widely available?
GLP-1 medicines are typically peptides, which are difficult to formulate as tablets because they break down during digestion. It has taken years of pharmaceutical development to create oral versions that absorb reliably.
Does having more treatment options make choosing harder for patients?
It can feel that way initially, but a proper consultation is designed to simplify the decision by narrowing options down to what is actually suitable and practical for your circumstances, rather than leaving you to compare everything alone.
Are oral GLP-1 medicines likely to become cheaper as more options launch?
Pricing depends on manufacturing costs, supply and demand, and is set independently by each provider. It is not guaranteed that increased competition will reduce prices, though it may improve overall availability.
Should I switch from an injection to a tablet now that more oral options exist?
This depends entirely on how you are responding to your current treatment. If your existing medication is working well for you, there is no clinical need to switch. Any change should be discussed with your prescriber first.
Does the number of new approvals in 2026 suggest these medicines are becoming safer?
Each medicine is assessed individually against UK regulatory standards before authorisation. A higher number of approvals reflects growing pharmaceutical innovation in this area, not a general loosening of safety requirements.
Is it worth waiting to see what launches next before starting treatment?
This is a personal decision, but treatment that is started and maintained consistently generally produces better outcomes than repeatedly delaying in anticipation of the next development.
A Year Of Genuine Change In Weight Loss Treatment
2026 has already reshaped what weight loss treatment looks like in the UK, and it is only August. From the Wegovy pill’s arrival in June to Foundayo’s landmark authorisation in August, patients now have more genuine choice than at any point in recent years. If you are trying to work out where you fit into this changing picture, our team is here to help you make sense of it.
Contact us today to discuss your options, or start a consultation to find the treatment that suits you.